The U.S. Food and Drug Administration has approved Casgevy, the first CRISPR-based gene therapy for sickle cell disease, marking a historic milestone in genomic medicine.

How It Works

The therapy uses CRISPR-Cas9 technology to edit the patient’s own hematopoietic stem cells, reactivating fetal hemoglobin production to compensate for the defective adult hemoglobin that causes sickle cell disease.

Clinical Trial Results

In clinical trials involving 98 patients, 96 percent remained free of severe pain crises for at least 18 months following treatment. The results were published in the New England Journal of Medicine.

Access and Cost

The one-time treatment costs $2.1 million, though insurance coverage and manufacturer patient assistance programs are expected to make it accessible to most patients. The Biden administration has announced a 10-year payment plan for Medicare and Medicaid beneficiaries.

Global Impact

Sickle cell disease affects approximately 20 million people worldwide, primarily those of African, Mediterranean, and Middle Eastern descent. The WHO has called for accelerated approval pathways in developing nations.